



Formulation and Evaluation of Self micro emulsifying drug delivery system of Piroxicam

¹Akshay Ghule, ²Shilpa Chaudhari, ³Priyatama Powar

¹Student, ²Associate Professor, ³Associate Professor

¹Pharmaceutics,

¹Dr. D. Y Patil College of Pharmacy, Akurdi, Pune, Maharashtra,

Abstract: BCS II lipid-lowering agent piroxicam. It is very little water-soluble and Phite buffer, pH 7.4, however it is not soluble in water solutions pH 4 along with lower. The current study aims to improve the the solvability and solubility of drugs that are inadequately soluble by developing a self-microemulsifies medication transport system that is SMEDDS. It was established whether Piroxicam was soluble in the separate microemulsion constituents, namely oil and surfactants. The ability of the surfactants to emulsify was tested. The solubility assessments and emulsification characteristics led to the selection of oil containing oleic acid and Tween 80 surfactants and PEG-8

Caprylic Capric Glyceride for more investigation. It was established how soluble proxicam was in various ratios of chosen oil to surfactants. For the formulation of SMEDDS, the oil:surfactant mixture with the highest solubility for piroxicam was utilized. A pseudoternary phase diagram was employed to assess the existence area of microemulsification. The development and screening of the formula was carried out according to the phase diagram results and the properties of the resulting microemulsions. The microemulsions were assessed for stability, in vitro dissolution, self-emulsification, phase separation, and emulsion droplet size. In contrast to the plain medication, which demonstrated a limited rate of dissolution, the SMEDDS formulation exhibited total release.

KEYWORDS: Piroxicam, SMEDDS, Surfactant, Cosurfactant and Oil.

I. INTRODUCTION

Piroxicam is an anti-inflammatory non-steroid medication used to treat painful contusions, rheumatoid arthritis, and osteoarthritis. It also has analgesic and antipyretic properties. It has, nevertheless, been linked to adverse gastrointestinal effects. By employing expanding drug suppliers that prevent direct drug contact with the stomach mucosa or that provide topical drug administration, these issues can be reduced to a minimum.

Choosing the right salt form, or adjusting the pH of the solution for liquid dosage documentation, is a crucial step in the solubilization of pharmacological molecules. For polar molecules in particular, this selection process is crucial because most of the more recent examples of solubilization, including microemulsions and nanosuspensions, need the use of co-solvents in the context of polar compounds (1). These technological encompass all of the traditional methods of improving solubility, as well as methods of reducing particle length by comminution, spray drying, adding surfactants, and incorporating them into cyclodextrin-drug complexes. Additionally, these technologies make use of additional advanced innovative methods like self-emulsifying systems, Using salting-in techniques, pH adjustments, and nanoparticles to achieve micronization (2, three).

Triglycerides additionally surfactants' reactivity with the gastrointestinal tract's partitions is thought to be the cause of the solubilizing and absorption-promoting impact of systems that self-emulsify and produce microemulsions, which have become known as technologies capable of improving solubility. Traditionally, medications have been introduced into self-emulsifying systems using long- along with medium-chain triglycerides (MCTs and LCTs, correspondingly) and surfactants (4, 5). High hydrophile-lipophile balances (HLB) are frequently employed in conjunction with non-ionic surfactants, Tweens (polysorbates), as well as polyoxyethylated oleic glycerides, or Labrafil to guarantee the prompt formation of oil-in-water (o/w) droplets at some point during the manufacturing process.

Better phases of drug solubilization can develop with amphiphilic, non-ionic surfactants, which may prevent the medication from precipitating within the in vivo microemulsion. Co-surfactants are widely utilized to boost the quantity that of medication that can dissolve into the lipid base because, in order for a surfactant to be fully self-emulsifying, its concentration must be at least 30% higher than% with weight. Often, these co-surfactants consist of organic solvents.

Properly formulated with ethanol, propylene glycol, and polyethylene glycol for oral delivery. Similar to the effects of adding natural solvents elsewhere in the production of pharmaceutical products, the addition of co-solvents will make processing more complex while simultaneously increasing the emulsion's potential drug load (6). Given that the product is liquid, the majority of self-emulsifies structures are restricted to management in fat-crammed tender or tough-molten gelatin pharmaceuticals. If you wish in order to stop the hydroscopic materials from drying out instead settling inside that tablet outer shell, you need to think about how the emulsion and tablet shell interact.

It is insoluble when mixed with water with a pH of four or lower and very little soluble in water with a pH of seven. Piroxicam has a high intestinal permeability on the physiologically relevant intestinal pH. Currently, SMEDDS for piroxicam are being arranged to improve the drug's soluble and dissolution of inadequately soluble components.

II. RESOURCES AND TECHNIQUES

RESOURCES:

We received a complimentary sample of Tween 80 and Piroxicam from Ajanta Pharma Ltd. in Mumbai, India. PEG 8-Caprylic Capric Glyceride was supplied expertly by Abitec Corp. of Janesville, Wisconsin. Analytical grade reagents and other chemicals had been used.

Solubility studies:

Piroxicam's solubility in a variety of Surfactants, co-surfactants, oils, and oils is determined using the shaking flask technique (eight–12). Each vehicle was seen to have an additional quantity of Piroxicam added after 30 seconds of vortex blending (Remi mixer, Mumbai). In a water bath with a thermostat, mixtures were shaken for 48 hours at 30 degrees Celsius before being left in equilibrium for 24 hours. Following a 10-minute centrifugation at 3000 rpm for the combinations, a Millipore membrane filter with a 0.45 μ opening was used to filter the supernatant. Drug awareness was determined after samples had unquestionably been diluted with methanol using a UV-validated technique that used methanol as a blank at 246 nm. Three copies of the test are administered. The effects are shown represent mean (mg/ml) \pm SEM. These were mixtures of surfactant and/or cosurfactant.

Preliminary screening of surfactants

The emulsification capacity of exceptional surfactants intended for oral application was examined. To put it succinctly, For every surfactant, 150 mg were combined with the oily phase in 150 mg. The combinations were heated progressively to 50 °C. in order to homogenize the additions. Next, using distilled water in a conical stopper flask, the 100 mg of each combination were diluted to 100 ml. The variety of inversions of flasks required to create a uniform emulsion was used to measure how easy emulsification was. Using distilled water as a blank and a UV-visible spectrophotometer made in Japan by Shimadzu, the % transmittance of the emulsions was determined after they had stood for two hours. In order to look for any turbidity or segment separation, the emulsions were also visually inspected.

Initial surfactant screening

Additionally, the unique co-surfactants have been screened for their potential to emulsify using the chosen oily section and surfactant. Tween 80 (400 mg), co-surfactant (200 mg), and oleic acid oil (600 mg) had all been arranged and assessed according to what was mentioned in the surfactant first screening.

Phase diagram take a look at:

Systems including oleic acid oil, Tween 80 as a surfactant, and PEG 8-Caprylic Capric Glyceride as a co-surfactant were titrated with water in a phase diagram that is pseudo-ternary analysis. Formulations that self-emulsify were chosen by examining areas of infinity

SMEDDS formulation:

Tween 80, PEG 8-Caprylic Capric Glyceride, and Oleic oil were used to develop a series of SMEDDS formulations due to the surfactant/cosurfactant composition. In short, oil, surfactant, and cosurfactant were added to a pitcher vial containing precisely weighed piroxam. The ingredients were then combined using a magnetic stirrer and light stirring and until the piroxam had totally dissolved, vortex mix. That aggregate was kept at room temperature until it was needed again.

III. SMEDDS EVALUATION

Phase separation and self-emulsification:

The distinct mixtures were arranged based upon the rate in terms of emulsification, transparency, and evident equilibrium of the emulsion that was produced (15, 16). The preconcentrate (SMEDDS) was added dropwise to pH 6.8 phosphate buffer, 0.01N HCl, and volumes of 100, 250, and 1,000 mL of pure water, respectively to perform a visible evaluation. This was done in a room-temperature glass beaker with a glass rod used to gently agitate the contents. Using a visual assessment of the last emulsion following a day, precipitation was assessed. The combinations were subsequently divided into four categories: solid (no precipitation at the end of the day), nonclear (turbid), volatile (precipitation within 24 hours), and clean (transparent or transparent with bluish tint).

Emulsion Droplet size:

Malvern Units, Malvern, United Kingdom's Laser Diffraction MasterSizer 2000 ver.2.00 determines the emulsion's particle length (8, 14). For the dimension, To make 250 mL of distilled water, the samples were diluted.

Drug content:

SMEDDS containing Piroxicam were added to a methanol-filled volumetric flask. For two hours, the liquid was vigorously mixed. After the proper dilution, the pattern is examined for piroxam attention using a UV spectrophotometer set 246 nanometers (5, 8, 13).

In vitro Disintegration:

Resting only on the material assessments of drug content, tough gelatin tablet shells containing 10 mg of piroxcam were packed with self-microemulsifying formulations. Using the dissolving test instrument of USP type II, the dissolution was in accomplished during 37 ± 50 C and Paddle speed of 50 revolutions per minute. Disintegration was attained in 2 distinct media: six.eight pH phosphate buffer (900 ml) and 0.1N HCl. After filtration via a 0.22μ filter, the samples were removed at pre-arranged intervals and subjected to UV-visible spectrophotometer analysis for drug attention (9, 17, 19, 20)

Stability studies:

During a three-month period, To examine the stability of the improved SMEDDS formula, the vials were subjected to stability testing at $40^\circ\text{C} \pm 2 \text{ } 0\text{C} / 75\% \pm 5\% \text{ RH}$ (2,21, 22). Thermolab in Mumbai, India has stability chambers that are equipped with temperature and humidity controls for charging samples. At predefined intervals, the samples were assessed for drug content, clarity, segment separation, and in vitro drug launch.

Table 4.1: Oil, Surfactant, Cosurfactant and their Absorbents.

Oil/surfactant/cosurfactant	232 nm	240 nm
Capmul MCM	0.218	0.207
Capmul PG 8	0.347	0.352
PEG 8 Caprylic Capric Glyceride	0.841	0.750
Transcutol CG	0.272	0.281
Tween 80	0.358	0.289
Oleic acid	0.292	0.280

Figure: pseudoternary phase diagram

Component Coding: Actual

All Responses


● Design Points

0.000 1.000

X1 = A

X2 = B

X3 = C



IV. RESULTS AND DISCUSSION

Solubility studies:

The creation of stable SMEDDS requires careful consideration of the appropriate element selection. To prevent drug precipitation during system shelf lives and after dilution in the GI lumen, the medication must have a desired solubility in the microemulsion's component parts. As a result, it was possible to assess how soluble Piroxicam was in different oils, cosurfactant mixes, and surfactants. The majority of the components under investigation, including PEG 8 Caprylic Capric Glyceride, Tween 80, and Oleic acid oil, confirmed maximal solubility.

The results of solubility Regarding oil: Since piroxicam was most soluble in oleic acid oil, PEG 8 caprylic capric glyceride, Tween 80, these were the chosen both the surfactant and the oil factors in light of the creation that of SMEDDS in a similar manner. The final choice among outstanding additives may also be verified in accordance with emulsification houses with additional substances. Drug solubility may be ranked second in terms of surfactant and co-surfactant selection, behind emulsification performance as the major selection criterion.

Preliminary screening of surfactants:

Using only oily levels, the surfactants were compared in light of their emulsification efficiency. It has been reported that under mild stirring circumstances, correctly prepared SNEDDS disperses in a matter of seconds. Tests are conducted on the transmittance values of various mixes. According to the results, Tween 80 ranked first among every surfactant used in the greasy stage, and Oleic acid oil had that best Emulsification process performance, necessitating only seven flask inversions (7 s) to generate a homogenous emulsion.

Preliminary screening of co-surfactants:

Co-surfactant addition increases the system's stability and dispensability in surfactant-containing formulations. Cosurfactants, namely transcutool CG and PEG 8 Caprylic Capric Glyceride, have been compared in light of state-of-the-art research. When compared to Transcutol CG, PEG 8 Caprylic Capric Glyceride demonstrated the highest transmittance due to its accurate emulsification using a blend of Oleic acid oil and Tween 80.

Pseudoternary phase diagrams:

Desk I shows the unique makeup of the SMEDDS formulations that were assembled into the segment diagram. Oleic acid oil is introduced to the device due to its excellent solubilizing capacity. When introduced into aqueous medium, Beautiful oil-water emulsions are created by self-microemulsifying devices with very little agitation. At the interface, the absorption of surfactant and co-surfactant is preferred, decreasing the interface voltage and putting up a mechanical defense that prevents fusion. That microemulsion formulations' thermodynamic balance is subsequently improved by the reduction inside the unbound energy needed to create an emulsion. Hydrophilic-lipophilic balance (HLB) surfactant and co-surfactant values are strongly correlated with their effectiveness of self-emulsification. Surfactants with an HLB of 12–15 are often seen to be sufficiently efficient for self-emulsification. The device selected to produce SMEDDS was thought to contain Tween 80 and PEG 8 Caprylic Capric Glyceride, Oleic acid oil, and other biocompatible excipients that were chosen due to their solubilizing properties and biocompatibility.

CONCLUSION:

The benefit of accurate piroxicam solubilization is provided by an optimized piroxicam loaded system that includes oleic acid oil, Tween 80, and PEG eight-Caprylic Capric Glyceride. Consequently, Our research revealed that SMEDDS may serve as a viable substitute for the traditional oral piroxicam method. Results also indicate that SMEDDS could be investigated as a potential medication supplier for piroxicam and other insoluble pill dissolution augmentation.

REFERENCES

- [1] Pouron CW. Evaluation of emulsification effectiveness in self-emulsifying drug delivery systems. *Int. J. Pharm.*, 27, 335–348, 1985.
- [2] Singh et al., Upadhyay S, Chaurasiya A, Mukherjee R, Khar R., and Singh M., Engineering and Enhancement of Exemestane-Loaded Self-Microemulsifies medication Transport Devices Vol. 9, No. 2, AAPS PharmSciTech, 2008, 628–634.
- [3] J.R. Robinson, 1996. Creation: Oral medication delivery systems using semi-solid formulations. *B. T. Gautéfosse*. 89:11–13.
- [4] N. Yuksel, Ozkan, SA., Baykara, T., Ozkan, Y., Savaser, A., and Karatas, A. (2003). Improved piroxicam's bioavailability when using Gelucire 44/14 with Labrasol: an assessment both in situ and in vitro. *J. Pharm. Biopharm. Eur.* 56, 453–459.
- [5] W.N. Charman, S.A. Charman, M.C. Rogge, T.D. Wilson, Pouton, and Charman 1992. The system as well as pharmacological assessment of an experimental lipophilous chemical for self-emulsifies medication transport systems. *Nine Pharma Res.*, 87-93.
- [6] Joshi, Y.M., Krill, S., Wagner, R.F., Ghosh, A., and Li, P., and A.T.M. Serajuddin, 2005. Impact that of using surfactants that are nonionic in combination upon the development in emulsions of oil in water. *Pharmacotherapy Int.* 288, 27–34.
- [7] Hee Jun Park, Min-Soo Kim, Jeong-Soo Kim, Sibeum Lee, Shun-Ji Jin, and Sung-Joo Hwang. Use of spray drying and SAS method to determine the physical-chemical properties and bioavailability of piroxicam. *10.1016/j.ijpharm.2008.04.006* is the doi.
- [8] In 2004, A article was published by Patil, Joshi, and Paradkar. Influence of formulation factors on the development and assessment of the gelled self-emulsifies medication transport system for ketoprofen. *E 42; AAPS PharmSciTech.* 5(three).

- [9] Okay, Zhang. Enhancement of Selfmicroemulsifying medication delivery methods for increasing Simvastatin oral bioavailability in Beagle dogs Int.J.Pharm,(2004)274,6573 B. Lee, Y.S. Yuk, H.S. Changa, G., and S.J. Chona, k.S. Jeong.
- [10] Ray, S., Ghosal, S., Bhandra, R., Subramanian, N., and Moulik, S. P. (2004). Celecoxib's gradual oral bioavailability thanks to the development of self-microemulsifying drug delivery devices. Bull. Biol. Pharm., 27(12), 1993-1999.
- [11] Li, Bummer, and Land (2005) examined the effects of the No. 2 lyceride oils' water content material about the steroid's solubility.21 Pharmaceutical Research, 254–260.
- [12] Enhanced silymarin bioavailability using self-microemulsifying medication transport device: Pharmaceutics and Biopharmaceutics in Europe 63 (2006) 288–294 Li Que, Yang Wang, and Wei Wu.
- [13] Zaghoul, A.A., Kh M.A., Shah, R., Palamakula, A., Nutan, M., Nazzal, S., and Raj, 2002. Impact of system components on the optimization of ubiquinone dose shape in self-nanoemulsified pills made with response surface technology.Intern. J. Pharm. 240, 103–114.
- [14] Grove and associates. (2006) improved and characterized self-microemulsifies medication transport structures for oral management including triglycerides, medium and long chains, therefore increasing the bioavailability of seocalcitol II. J. Pharm. Sci. Eur., 28(3), 233-242.
- [15] Eur. Journal of Pharm. Sci. 35 (2008) 257–263, Phenytoin Self-Emulsifies medication transport Systems formulation and in vitro and in vivo characterization.
- [16] Stronger taking up of indomethacin following either oral or rectal management of Self-emulsifies medication transport device has Indomethacin in it, J. Y. Kim, and Young, S. Ok. (2000)J. Int. Pharmacol., 194, 81–89.
- [17] C.W. Pouton and W.N. Charman, 1997. that possibility that of fatty formulations carrying drugs into the gastrointestinal system. Expert Medicine Del. Rev. 25, 1-2.
- [18] Polystyrene beads with pores serving as carriers for loperamide in a self-emulsifying system. According to Pathil and Paradkar (2006), AAPS PharmSciTech (2006), 7 (1) Article 28
- [19] USP apparatus 3 for instantaneously launch product dissolving testing was assessed by Yu, X. L., Wang, T.J., and Hussain, S.A. (2002); AAPS Pharmsci., article 4(1).
- [20] Kroon, OK.G., Hoglund, P., Kaufmann, P., and Odeberg, J. M. (2003). Lipid drug administration and rational procedure layout for lipophilic drugs with limited oral bioavailability, applied to cyclosporine. Eur. J.Pharm.Sci, 20, 375-382.
- [21] In Vivo Evaluation and Guidelines for SMEDDS (Self- Microemulsifies medication transport system) Containing Fenofibrate, Patel A. and Vavia P., The AAPS journal 2007; nine(3), Article 41.
- [22] "Enhancing of oralabsorption of curcumin by using self microemulsifying drug delivery structures," International Journal of Pharmaceutical Sciences (2008),+ doi:10.1016/j.Ijpharm.2008.12.0090, Yu Z., Weiwei Z., Bo Y., Jing C., Houli L., Hongxiang L., Guangxi Z.